Siemens is proud to announce that – according to an independent study – our DCA Vantage® Analyzer is one of just two HbA1c analyzers that meets tightened performance criteria set by the NGSP*.
The European Reference Laboratory for Glycohemoglobin study’s results were published in Clinical Chemistry as "Six of Eight Hemoglobin A1c Point-of-Care Instruments Do Not Meet the General Accepted Analytical Performance Criteria" (January 2010, 56:1).
The study objective was to "evaluate all available HbA1c POC instruments according to CLSI protocols and to check whether the instruments would pass the NGSP criteria with 2 different reagent lot numbers."1
HbA1c analyzers evaluated were:
- A1c Now (Bayer)
- Afinion and Nycocard (Axis-Shield)
- Clover (Infopia)
- DCA Vantage (Siemens)
- In2it (BioRad)
- InnovaStar (Diasys)
- Quo-Test (Quotient Diagnostics)
According to the results, only two POC instruments met the acceptance criteria and the DCA Vantage analyzer was one of them.
Read the full article, "Six of Eight Hemoglobin A1c Point-of-Care Instruments Do Not Meet the General Accepted Analytical Performance Criteria", on Clinical Chemistry
The DCA Vantage Analyzer now provides dual reporting, using the IFCC-NGSP master equation.